Go to content

Lukt het niet om in te loggen op het AFM Portaal?

Het kan helpen om uw browsergeschiedenis/cookies te verwijderen

Crucell N.V.

Crucell N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 18 dec 2008 - 08:00
Statutaire naam Crucell N.V.
Titel DSM Biologics and Crucell Announce PER.C6® Research License Agreement with GlaxoSmithKline
Bericht Leiden, The Netherlands/Parsippany, USA, 18 December 2008 – DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that GlaxoSmithKline (GSK) signed a license agreement allowing GSK to research a recombinant protein on the PER.C6® platform. Financial terms of the agreement were not disclosed. “We are very pleased to enter into this collaboration with GSK”, said Ronald Brus, Crucell's Chief Executive Officer. “This agreement further underscores the potential of our PER.C6® production technology for generating recombinant proteins.” “The PER.C6® production technology continues to surpass our expectations as a robust manufacturing platform with its ever extending and global reach into the Research and Development departments of major healthcare players,” adds Karen King, President of DSM Biologics. “This agreement with GSK brings us closer to our mission of making PER.C6® technology a gold standard for industry use.”

Datum laatste update: 01 maart 2024